Harwood Feffer LLP Announces Investigation of Allos Therapeutics, Inc.
20 Julho 2011 - 1:16PM
Business Wire
Harwood Feffer LLP (www.hfesq.com)
is investigating potential claims against the board of directors of
Allos Therapeutics, Inc. (“Allos” or the “Company”) (NASDAQ: ALTH)
concerning AMAG Pharmaceuticals, Inc.’s (“AMAG”) (NASDAQ: AMAG)
offer to buy the Company in an all-stock deal that values the
Company at approximately $285 million. Under the terms of the
proposed transaction, Allos shareholders will receive a fixed ratio
of 0.1282 shares of AMAG common stock for each share of Allos
common stock they own, valuing Allos stock at $2.44 a share based
on yesterday’s closing price of AMAG shares.
Our investigation concerns whether the board of directors is
undertaking a fair process to obtain fair consideration for all
shareholders of Allos.
If you own shares of Allos and would like to learn more about
these claims or if you wish to discuss this matter and have any
questions or information concerning this announcement, please
contact Robert I. Harwood, Esq. at rharwood@hfesq.com or Peter W.
Overs, Jr., Esq. at povers@hfesq.com. You may also call them at
(877) 935-7400. For more information about class actions, or to
sign up online, please visit our website: www.hfesq.com.
Harwood Feffer LLP is a national shareholder litigation firm.
Harwood Feffer LLP is devoted to protecting the interests of
individual and institutional investors in shareholder actions in
state and federal courts nationwide.
Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP
(www.hfesq.com). Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Harwood Feffer LLP